Startups
SynDevRx is a leader in the growing field of Metabo-Oncology, illuminating the link between cancer and metabolic hormone dysfunction to find effective therapies.
Overview
Employees
11-50
Founded date
2007
Mentions in press and media 7
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| May 19, 2026 | SynDevRx to Present AMELIA™-1 Data at ASCO 2026 Showing Improved PI3K/AKT Class Inhibitor Responses in Breast Cancer | Evexomostat combination shows clinical benefit and favorable safety in heavily pretreated HR+/HER2− mBC patients with PI3K pathway alterations. The PI3K/AKT inhibitor class has clinical benefit, but durability is limited. We believe targeti... |
| Jan 9, 2025 | $1.2M Grant Awarded for Groundbreaking Prostate Cancer Research on SynDevRx MetAP2 Inhibitor 'Evexomostat' | Award follows extensive pre-clinical, single agent activity data generated by Prof. Colleen Nelson’s lab at QUT in ‘Aggressive Variant’ prostate cancer models By integrating our research strengths with SynDevRx’s innovative therapeutic appr... |
| Aug 3, 2021 | SynDevRx Announces Research Collaboration with Maine Medical Center Research Institute to Study the Effects of SDX-7320 In Obesity-Accelerated Multiple Myeloma Models | “We’re excited to test this drug, SDX-7320, in these models of cancers accelerated by obesity,” lead investigator Michaela Reagan, PhD, said. “Obesity changes the composition of the blood and bone marrow, making it more conducive for multip... |
| Jan 16, 2008 | Folkman Leaves Behind an Inspiring Legacy of Science, Learning, and Startups | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Back when I was starting out in some lowly jobs at the Longwood Medical area, I was constantly reminded of the greatness of certain of the people around me. But one of those p... |
| Jan 14, 2008 | Life sciences briefing: Monday, Jan. 14, 2008 | TODAY’S HEADLINES: Autonomic Technologies raises $3M for neurostimulators (PE Hub) Canopy Financial raises $15M for outsourced healthcare management (release) Cancer-drug developer AmpliMed draws $5M (PE Hub) Caprotec Bioanalytics receives ... |
| Syndevrx | “SynDevRx leads the field of Metabo-Oncology, exploiting the link between cancer and metabolic dysfunction to improve patient outcomes.” |
Reviews 0
FAQ about SynDevRx
When was SynDevRx founded?
SynDevRx was founded in 2007.
What has the press written about SynDevRx?
Parsers VC has collected 7 articles mentioning SynDevRx, among them “SynDevRx to Present AMELIA™-1 Data at ASCO 2026 Showing Improved PI3K/AKT Class Inhibitor Responses in Breast Cancer” (May 19, 2026) and “$1.2M Grant Awarded for Groundbreaking Prostate Cancer Research on SynDevRx MetAP2 Inhibitor 'Evexomostat'” (Jan 9, 2025).
Is SynDevRx still active?
Yes, SynDevRx is active; its latest activity on Parsers VC dates from Oct 20, 2026.